Brief: Valbiotis Launches Cash Capital Increase Of Around 12 Million Euros

Valbiotis SA

14/04/2021 16:48

April 14 (Reuters) - Valbiotis SA  ALVAL.PA :
    * VALBIOTIS LAUNCHES A CAPITAL INCREASE THROUGH A PRIVATE
PLACEMENT
    * LAUNCH OF A CASH CAPITAL INCREASE OF APPROXIMATELY 12
MILLION
EUROS USING AN ACCELERATED BOOKBUILDING PROCESS
    * NET PROCEEDS OF CAPITAL INCREASE ARE INTENDED PRIMARILY TO
FINANCE ACCELERATION OF DEVELOPMENT OF TOTUM 854
    * WILL ENABLE: FINANCING COMPANY'S OVERALL COSTS UNTIL
SUMMER 2023
    * TOTUM 854: PLANS TO LAUNCH THREE CLINICAL TRIALS AT END OF
THIS
YEAR INCLUDING PHASE II/III CLINICAL TRIAL, PRIOR TO HEALTH
CLAIM APPLICATION
    * ACCELERATED BOOKBUILDING PROCESS WILL BEGIN IMMEDIATELY
AND
SHOULD BE CONCLUDED BEFORE OPENING OF MARKETS ON APRIL 15, 2021
    * IN PARTNERSHIP WITH MAJOR HEALTHCARE PLAYER, TOTUM 854
COULD
THEN BE MARKETED AT END OF THIS STUDY, UP TO 3 YEARS AHEAD OF
INITIAL SCHEDULE
    * WILL ENABLE: REINFORCEMENT OF STAFF, MAINLY CLINICAL AND
SUPPLY
CHAIN TEAMS, TO PREPARE UPCOMING MARKETING OF TOTUM63 IN
PREDIABETES BY NESTLÉ HEALTH SCIENCE
    * WILL ENABLE: FUNDING OF PRECLINICAL RESEARCH ON OTHER
PRODUCTS
IN PORTFOLIO

Source text for Eikon:  ID:nBw29nQRsa 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))